The Role of 18F-FDG PET/CT as a Prognostic Factor in Patients with Synovial Sarcoma

被引：34

作者：

Chang K.J. ^{[1
]}

Lim I. ^{[1
]}

Park J.Y. ^{[1
]}

Jo A.R. ^{[1
]}

Kong C.B. ^{[2
]}

Song W.S. ^{[2
]}

Jo W.H. ^{[2
]}

Lee S.Y. ^{[2
]}

Koh J.S. ^{[3
]}

Kim B.I. ^{[1
]}

Choi C.W. ^{[1
]}

Lim S.M. ^{[1
]}

机构：

[1] Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowongil, Nowon Gu, 139-706, Seoul

[2] Department of Orthopedics, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul

[3] Department of Pathology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul

来源：

Nuclear Medicine and Molecular Imaging | 2015年 / 49卷 / 1期

关键词：

!sup]18[!/sup]F-FDG PET/CT; Prediction; Prognosis; Survival; Synovial sarcoma;

D O I：

10.1007/s13139-014-0301-5

中图分类号：

学科分类号：

摘要：

Purpose: This research aims to investigate the potential of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET) to predict pathologic response after neoadjuvant chemotherapy (NAC) and overall survival (OS) of patients with synovial sarcoma in Korea. Methods: Twenty patients with synovial sarcoma from January 2001 to December 2011 were reviewed retrospectively. All patients underwent pre-treatment FDG PET and tumor removal. Patients were classified with the maximum SUV (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), age, sex, histologic subtype, tumor size, NAC, resection margin, and metastasis at diagnosis. Pathologic response was assessed using the French Federation of Cancer Centers system. Statistical analyses were analyzed using the Kaplan-Meier method, log-rank test, Cox proportional hazards regression model, and Mann-Whitney test. Results: Nine patients (45 %) showed pathologic response, and ten patients survived. Higher SUVmax, higher MTV, higher TLG, monophasic epithelial type, and metastasis at diagnosis were significantly related to poorer OS (p = 0.047, 0.016, 0.016, 0.045, and 0.018, respectively). By multivariate analysis, metastasis at diagnosis was significantly related to poorer OS (p = 0.012/HR = 5.9, 95 % CI 1.47 to 24.1). The SUVmax, MTV, and TLG of the non-responder group were significantly higher than those of the responder group (p = 0.020, 0.020, and 0.020, respectively). There was no significant difference in size between the two groups (p = 0.062). Conclusions: A higher SUVmax on the pre-treatment scan, monophasic epithelial type, and metastasis at diagnosis were significantly associated with a poorer OS, and pathologic responders showed a higher SUVmax before NAC. The PET parameters can be used to predict OS and pathologic response in patients with synovial sarcomas before NAC. © 2014, Korean Society of Nuclear Medicine.

引用

页码：33 / 41

页数：8

共 42 条

[1]

Deshmukh R., Mankin H.J., Singer S., Synovial sarcoma: the importance of size and location for survival, Clin Orthop Relat Res, 419, pp. 155-161, (2004)

[2]

Bergh P., Meis-Kindblom J.M., Gherlinzoni F., Berlin O., Bacchini P., Bertoni F., Et al., Synovial sarcoma: identification of low and high risk groups, Cancer, 85, pp. 2596-2607, (1999)

[3]

Singer S., Baldini E.H., Demetri G.D., Fletcher J.A., Corson J.M., Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival, J Clin Oncol, 14, pp. 1201-1208, (1996)

[4]

Lewis J.J., Antonescu C.R., Leung D.H., Blumberg D., Healey J.H., Woodruff J.M., Et al., Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity, J Clin Oncol, 18, pp. 2087-2094, (2000)

[5]

Stanelle E.J., Christison-Lagay E.R., Healey J.H., Singer S., Meyers P.A., La Quaglia M.P., Pediatric and adolescent synovial sarcoma: multivariate analysis of prognostic factors and survival outcomes, Ann Surg Oncol, 20, pp. 73-79, (2013)

[6]

Trassard M., Le Doussal V., Hacene K., Terrier P., Ranchere D., Guillou L., Et al., Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients, J Clin Oncol, 19, pp. 525-534, (2001)

[7]

Spurrell E.L., Fisher C., Thomas J.M., Judson I.R., Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital, Ann Oncol, 16, pp. 437-444, (2005)

[8]

Ngahane B.H., Baudrand H., Traverse-Glehen A., Freymond N., Guibert B., Pacheco Y., Et al., Assessment of prognostic factors of thoracic synovial sarcoma, Rev Mal Respir, 27, pp. 93-97, (2010)

[9]

Cheon G.J., Kim M.S., Lee J.A., Lee S.Y., Cho W.H., Song W.S., Et al., Prediction model of chemotherapy response in osteosarcoma by 18 F-FDG PET and MRI, J Nucl Med, 50, pp. 1435-1440, (2009)

[10]

Abdelsalam M., Bazarbashi S., Abouzied M., Amin T., Soudy H., Rahal M., Et al., Whoe body 18 F-FDG PET predicts progression free and overall survival in squamous cell carcinoma of the esophagus: results of a prospective trials, Hematol Oncol Stem Cell Ther, 3, pp. 179-184, (2010)

← 1 2 3 4 5 →